MedWatch

William Demant and GN on intensified US competition: Monitoring the situation but see no threat

Danish hearing device groups William Demant and GN Hearing retain their composure after news from the rival Bose resulted in nosediving share prices. However, the companies monitor the situation very closely. Analyst calls the stock market's reaction "extremely exaggerated."

Foto: William Demant Holding/ PR

Danish hearing aid group William Demant has gotten food for thought after US-based company Bose launched a new hearing device and last week received FDA's approval.

"We can conclude that FDA has approved a device, which is apparently a hearing aid based on user-centered adjustment. We don't know anything about the product itself, how it works and what it looks like, but we assume that it complies with the rules for marketing and sales," says Trine Kromann-Mikkelsen, Vice President, Corporate Communication & Relations, in William Demant.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier